500 related articles for article (PubMed ID: 31555580)
1. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
Rice MA; Malhotra SV; Stoyanova T
Front Oncol; 2019; 9():801. PubMed ID: 31555580
[TBL] [Abstract][Full Text] [Related]
2. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer.
Mitsogianni M; Papatsoris A; Bala VM; Issa H; Moussa M; Mitsogiannis I
Expert Opin Pharmacother; 2023; 24(16):1765-1774. PubMed ID: 37545430
[TBL] [Abstract][Full Text] [Related]
6. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
Verma S; Prajapati KS; Kushwaha PP; Shuaib M; Kumar Singh A; Kumar S; Gupta S
Cancer Drug Resist; 2020; 3(4):742-761. PubMed ID: 35582225
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.
Pinto F; Dibitetto F; Ragonese M; Bassi P
Med Sci (Basel); 2022 Apr; 10(2):. PubMed ID: 35645241
[TBL] [Abstract][Full Text] [Related]
9. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
10. Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Orme JJ; Pagliaro LC; Quevedo JF; Park SS; Costello BA
Oncologist; 2022 Mar; 27(2):110-124. PubMed ID: 35641216
[TBL] [Abstract][Full Text] [Related]
11. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer.
Feng Q; He B
Front Oncol; 2019; 9():858. PubMed ID: 31552182
[TBL] [Abstract][Full Text] [Related]
13. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
14. Hormonal Therapy for Prostate Cancer.
Desai K; McManus JM; Sharifi N
Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
16. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K
Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.
Ito Y; Sadar MD
Res Rep Urol; 2018; 10():23-32. PubMed ID: 29497605
[TBL] [Abstract][Full Text] [Related]
18. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Imamura Y; Sadar MD
Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]